Perform Another (Advanced) Search

1.  Study Posting (2348) Trial #46362, Leukemia, New York, NY
...Posting (2348) Trial #46362, Leukemia, New York, NY Trial Information Randomized Phase II Study of Thalidomide Versus Thalidomide Plus Fludarabine for Patients with Chronic Lymphocytic Leukemia Previously Treated with Fludarabine Patients with chronic ...
View Page

2.  Study Posting (713) Trial #27666, Lung Cancer, Charlottesville, VA
...VA Trial Information Phase III trial of Carboplatin/Paclitaxel and thoracic radiation with or without Thalidomide in patients with stage III non-small cell lung cancer. HIC #8779 This study is ...
...effusion are randomized to either receive induction Carboplatin/Paclitaxel followed by radiation in addition to Thalidomide starting on day 1 vs. induction Paclitaxel/Carboplatin followed by radiation without Thalidomide. The inclusion ...
View Page

3.  Study Posting (2348) Trial #87098, Ovarian Cancer, New York, NY
...Trial #87098, Ovarian Cancer, New York, NY Trial Information A Randomized Study of Tamoxifen Versus Thalidomide (NSC# 66847) in Patients with Biochemical-Recurrence-Only-Epithelial Ovarian Cancer, Cancer of the Fallopian ...
...abdominal cavity). The purpose of this study is to determine which of the following drugs, thalidomide or tamoxifen, may help to prevent the cancer from returning for the longest period of ...
View Page

4.  Study Posting (2246) Trial #70987, Multiple Myelomas, Duarte, CA
...Melphalan and Total Marrow Irradiation (TMI) with Peripheral Blood Progenitor Cell Support and Dexamethasone and Thalidomide Maintenance in Multiple Myeloma: A Phase I/II Trial You have been asked to participate ...
...dose of TMI that can be given without causing unmanageable side effects. Afterwards, Dexamethasone and Thalidomide will be given to help maintain any benefit obtained from the two cycles of high ...
View Page

5.  Newly Approved Drug Therapies (460) Thalomid, Celgene,
...Thalomid Company: Celgene Approval Status: Approved July 1998 Treatment Area: Dermatology General Information The drug thalidomide has a long FDA history. It was approved in Europe in 1957, but was rejected ...
...of the drug. While the Agency was awaiting answers to these concerns, the link between thalidomide use and an epidemic of congenital malformations was recognized and the drug was then withdrawn ...
View Page

6.  CenterWatch: New Medical Therapies in Disease Category (808), Bone Diseases
...Musculoskeletal December 16, 2002 Celgene reported positive results from a phase II trial investigating Thalomid (thalidomide) in combination with prednisone for the treatment of myelofibrosis. The data demonstrated that 13 of ...
View Page

7.  CenterWatch: New Medical Therapies in Disease Category (47), Collagen Vascular Diseases
...Diseases December 16, 2002 Celgene reported positive results from a phase II trial investigating Thalomid (thalidomide) in combination with prednisone for the treatment of myelofibrosis. The data demonstrated that 13 of ...
View Page

8.  Newly Approved Drug Therapies (889) Revlimid (lenalidomide), Celgene,
...Approved December 2005 Treatment Area: Myelodysplastic Syndromes General Information Revlimid (lenalidomide) is an orally available thalidomide analog, exerting both anti-angiogenic and immunomodulatory/anti-inflammatory properties. Revlimid is specifically indicated for ...
...these studies in two different species that are appropriate to assess the full range of thalidomide embryo-fetal effects. As discussed, the rat is not an acceptable model. If the study ...
View Page

9.  Study Posting (180) Trial #88174, Multiple Myelomas, New York, NY
...for the treatment of multiple myeloma. CC-5013 is a drug that is related to thalidomide. In lab experiments using it against myeloma cells, CC-5013 is much stronger than thalidomide. In clinical studies involving about 60 people who had myeloma that did not respond to ...
View Page

10.  Study Posting (2246) Trial #147038, Multiple Myelomas, Duarte, CA
...MELPHALAN AND TOTAL MARROW IRRADIATION (TMI) WITH PERIPHERAL BLOOD PROGENITOR CELL SUPPORT AND DEXAMETHASONE AND THALIDOMIDE MAINTENANCE: A PHASE I/II TRIAL. The purpose of this study is monitor side effects ...
View Page

11.  Study Posting (2246) Trial #121294, Multiple Myelomas, Duarte, CA
...carfilzomib in subjects with multiple myeloma who have previously received the medication bortezomib with either thalidomide or lenalidomide.   Your treatment on this study is expected to last at least 2 months ...
View Page

12.  Study Posting (709) Trial #109114, Skin Infections/Disorders, Stanford, CA
...planus treatment (e.g. cyclosporine, systemic retinoids, hydroxychloroquine, chlorquine, quinacrine, azathioprine, methotrexate, mycophenolate mofetil, dapsone, thalidomide, PUVA, UVB) except for prednisone for 4 weeks prior to starting the study drug • If ...
View Page

13.  CenterWatch: New Medical Therapies in Disease Category (52), Cutaneous T-Cell Lymphoma
...results from a phase I/II, investigator-initiated trial with Velcade (bortezomib) in combination with thalidomide with dexamethasone for the treatment of advanced stage multiple myeloma. Of the 56 subjects who are currently enrolled in the trial, 96% received prior autotransplant and 81% received prior thalidomide. Investigators reported that responses were observed in subjects who had previously received thalidomide treatment, and ...
View Page

14.  CenterWatch: New Medical Therapies in Disease Category (129), Red Cell Disorders
...future. December 16, 2002 Celgene reported positive results from a phase II trial investigating Thalomid (thalidomide) in combination with prednisone for the treatment of myelofibrosis. The data demonstrated that 13 of ...
View Page

15.  CenterWatch: New Medical Therapies in Disease Category (212), Multiple Myelomas
...trial. Celgene announced final results from a phase III trial investigating their approved drug Thalomid (thalidomide) for the treatment of multiple myeloma. Results from the study indicate that the addition of ...
...results from a phase I/II, investigator-initiated trial with Velcade (bortezomib) in combination with thalidomide with dexamethasone for the treatment of advanced stage multiple myeloma. Of the 56 subjects who ...
View Page

16.  Study Posting (77) Trial #117022, Lupus, Manhasset, NY
...day, azathioprine greater than 3mg/kg/day or any dose of dapsone, cyclophosphamide, cyclosporine or thalidomide • Have received doses of antimalarials, mycophenolate mofetil, methotrexate, leflunomide, or azathioprine within 28 prior to ...
View Page

17.  Study Posting (1918) Trial #85467, Adenocarcinoma, Savannah, GA
...acetate . • No prior cytotoxic chemo, including estramustine or suramin. • No prior anti-angiogenesis agents, including thalidomide and bevacizumab. • No known brain mets. No current CHF. • Any hypertension, must be well-controlled ...
View Page

18.  Study Posting (77) Trial #120733, Small Cell Lung Cancer, Jamaica, NY
...inhibitors (with the exception of bevacizumab), or other angiogenesis inhibitors (including but not limited to thalidomide) • Have had major surgery within 4 weeks of first study treatment • Have a tumor (any ...
View Page

19.  Study Posting (557) Trial #137317, Lupus, Clearwater, FL
...Leflunomide >20 mg/day • Azathioprine >3 mg/kg/day • Cyclophosphamide Any dosage • Cyclosporine Any dosage • Thalidomide Any dosage • Not have a history of severe viral infections • Not have been vaccinated with ...
View Page

20.  Study Posting (4959) Trial #157055, Chronic Lymphocytic Leukemia, New York, NY
...MM – refractory to or relapsed after at least 2 prior chemotherapy regimens, including bortezomib and thalidomide or lenalidomide (except if the drug is contraindicated in a patient then this requirement is ...
View Page